Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating bronchoscopic lung volume reduction using thermoablation as a treatment for patients with severe emphysema. This prospective, two-arm, randomized, open-label trial compares this intervention combined with standard conservative therapy against standard therapy alone, following Global Initiative for Chronic Obstructive Lung Disease GOLD guidelines. The study aims to contribute evidence on the benefits and safety of this procedure to provide appropriate care for emphysema patients. The trial involves two groups one receiving bronchoscopic lung volume reduction with thermal ablation using the InterVaporAE System in addition to standard care, and the other receiving only standard conservative therapy. The InterVaporAE System delivers heated water vapor to targeted lung areas, causing tissue remodeling and volume reduction. Participants in the intervention group may receive up to two partial treatments. Participants will be monitored over several months with assessments including patient-reported quality of life, lung function tests like FEV1 and residual volume, vital status checks, 6-minute walk tests, and monitoring for serious adverse events and exacerbations. Follow-up evaluations occur at 3, 9, and 12 months, with the primary outcome measured at 9 months. The study duration and procedures are designed to evaluate the impact and safety of the bronchoscopic treatment compared to standard care.
Actively Recruiting
Researchers are gathering real-world data from patients in Germany with non-squamous metastatic non-small cell lung cancer NSQ mNSCLC, including large cell neuroendocrine carcinoma when considered similar to NSCLC. The study focuses on patients beginning their first-line treatment with a combination of tremelimumab, durvalumab, and platinum-based chemotherapy TDC as approved. It aims to understand treatment effectiveness based on specific genetic mutations like KRAS, STK11, KEAP1, TP53, and markers such as TTF-1 and PD-L1 to help guide personalized treatment strategies for high-need patient subgroups. Participants are observed without receiving additional interventions beyond their planned standard treatment with TDC. The study collects data according to routine clinical practice during the patients treatment course. Biomarker testing including molecular sequencing and expression analyses is performed as per institutional standards to classify patient subgroups. During the study, participants survival and treatment responses are tracked for up to 24 months, with key outcomes including real-world overall survival rates at two years, progression-free survival, and safety through adverse event collection. Data are gathered at multiple time points up to two years to evaluate outcomes in the overall population and in subgroups defined by genetic mutations. Participants provide informed consent and must meet specific eligibility criteria to join.